MedTrace Logo

Evaluation of the Role of Acetyl Cysteine in Ventilator Associated Pneumonia by Carbapenem Resistance Klebsiella

NCT07097727 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-07-31

No results posted yet for this study

Summary

The aim of the study is to evaluate the role of addition of Acetyl cysteine in the management of VAP induced by carbapenem resistant klebsiella. The primary outcome indicator is the change in modified clinical pulmonary infection score. The secondary outcome indicator is duration of mechanical ventilation.

Conditions

  • Ventilator Associated Pneumonia ( VAP)
  • Mechanical Ventilation

Interventions

DRUG

acetyl cysteine 600 mg

patients received acetyl cysteine 600 mg/ 12h IV in addition to antibiotics

DRUG

antibiotics and saline.

patients received only antibiotics and saline

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Wessam Elfeky, Resident · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2024-09-30
Completion
2024-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07097727 on ClinicalTrials.gov